NCT02119832已完成不适用
A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- C. R. Bard
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Adverse Events
研究概览
简要总结
The primary objective of this clinical study is to evaluate the preliminary safety and effectiveness of using the FLEX-1 device for the creation of an arteriovenous fistula (AVF) including coiling of the brachial vein during the index procedure in patients requiring chronic hemodialysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible for a native surgical arteriovenous fistula, as determined by the treating physician.
- •Adult (age >18 years old).
- •Advanced chronic kidney disease (CKD), stage 4 or 5 electing for hemodialysis.
- •Written informed consent obtained
排除标准
- 未提供
结局指标
主要结局
Adverse Events
时间窗: 6 months
The safety of the FLEX-1 system based on the overall complication rates derived from adverse event data.
次要结局
- Access Functionality(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-001Chronic Kidney Disease (CKD)NCT02119845C. R. Bard16
已完成
不适用
A Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical ProlapsePelvic Organ ProlapseNCT01111409Ethicon, Inc.20
终止
1 期
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid TumorsRefractory CancerNCT02222363Vivolux AB19
进行中（未招募）
不适用
Investigating Bone Cement With or Without Inossia® Cement Softener for Vertebral Compression FracturesVertebral Compression FractureNCT05676320Inossia AB203
尚未招募
1 期
A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) TreatmentSteroid-refractory Acute Graft-versus-host DiseaseNCT06677255Wuhan Optics Valley Vcanbiopharma Co., Ltd.149